Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
38 hedge funds and large institutions have $16.8M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
47% more call options, than puts
Call options by funds: $298K | Put options by funds: $203K
5% less funds holding
Funds holding: 40 → 38 (-2)
15% less capital invested
Capital invested by funds: $19.9M → $16.8M (-$3.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.32M |
| 2 |
AIC
AWM Investment Company
New York
|
+$505K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$303K |
| 4 |
Renaissance Technologies
New York
|
+$279K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.28M |
| 2 |
KAM
Krensavage Asset Management
New York
|
-$241K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$116K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$106K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
-$59.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $33K | +$187 | +37 | +0.5% |
|
|
PAM
27
Panagora Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
|
AIM
28
Acrospire Investment Management
Chicago,
Illinois
| $8K | +$8.11K | +1,605 | New |
|
|
ECM
29
Estabrook Capital Management
New York
| $7.13K | – | – | – |
|
|
NFA
30
Nationwide Fund Advisors
Columbus,
Ohio
| $5K | – | – | – |
|
31
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | – | – | – |
|
32
Barclays
London,
United Kingdom
| $2K | +$2.51K | +497 | New |
|
33
UBS Group
Zurich,
Switzerland
| $1K | -$19.2K | -3,791 | -96% |
|
|
FWM
34
Focused Wealth Management
Newburgh,
New York
| $1K | – | – | – |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $1K | +$828 | +164 | New |
|
36
Walleye Trading
New York
| $15 | +$8.08K | +1,600 | +100% |
|
|
SCM
37
Stonepine Capital Management
Bend,
Oregon
| – | -$1.28M | -228,392 | Closed |
|
|
GCP
38
GSA Capital Partners
London,
United Kingdom
| – | -$116K | -20,792 | Closed |
|
39
Russell Investments Group
London,
United Kingdom
| – | -$1K | -200 | Closed |
|
JNP Hedge Fund Activity: Q1 2017 in Review
38 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2017, worth a combined $16.8M — down 15% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new JNP positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $3.32M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.28M sold.
- 38 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2017, down from 40 in Q4 2016.
- Funds reported $16.8M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2017, down 15% quarter-over-quarter.
- 7 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2017 and 3 closed out, a net change of +4 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $3.32M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2017 was Stonepine Capital Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q1 2017.